Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Prudential Financial Inc.

Prudential Financial Inc. lessened its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 20.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 96,817 shares of the company’s stock after selling 25,273 shares during the quarter. Prudential Financial Inc.’s holdings in Kymera Therapeutics were worth $3,895,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in KYMR. Vanguard Group Inc. raised its position in Kymera Therapeutics by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company’s stock worth $196,617,000 after acquiring an additional 133,546 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Kymera Therapeutics during the 4th quarter worth approximately $310,000. Teacher Retirement System of Texas lifted its stake in Kymera Therapeutics by 35.8% in the 4th quarter. Teacher Retirement System of Texas now owns 11,490 shares of the company’s stock valued at $462,000 after buying an additional 3,026 shares in the last quarter. Swiss National Bank lifted its stake in Kymera Therapeutics by 15.6% in the 4th quarter. Swiss National Bank now owns 76,200 shares of the company’s stock valued at $3,066,000 after buying an additional 10,300 shares in the last quarter. Finally, E Fund Management Co. Ltd. increased its position in Kymera Therapeutics by 23.5% during the fourth quarter. E Fund Management Co. Ltd. now owns 67,068 shares of the company’s stock worth $2,698,000 after buying an additional 12,776 shares in the last quarter.

Insider Activity

In other news, insider Ellen Chiniara sold 2,241 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $68,238.45. Following the completion of the sale, the insider now owns 80,085 shares in the company, valued at approximately $2,438,588.25. This trade represents a 2.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Bruce N. Jacobs sold 7,035 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the transaction, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.70. This trade represents a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,788 shares of company stock valued at $455,202. Company insiders own 15.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on KYMR shares. Leerink Partners restated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Friday, December 27th. Citigroup assumed coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $52.00 price target on the stock. BTIG Research started coverage on shares of Kymera Therapeutics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price objective for the company. Stephens restated an “overweight” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Finally, HC Wainwright boosted their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a report on Friday, February 28th. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $56.36.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock opened at $25.24 on Wednesday. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -10.79 and a beta of 2.22. Kymera Therapeutics, Inc. has a 12 month low of $24.36 and a 12 month high of $53.27. The stock’s 50-day moving average is $35.23 and its 200-day moving average is $41.48.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The business had revenue of $7.39 million during the quarter, compared to analysts’ expectations of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.